---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-030354"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T06:27:35.003289+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cellectar FY2022 net loss $28.6M ($4.05/share); cash $19.9M, runs to Q4 2023

## Summary
- Net loss $28.6M ($4.05/share) vs $24.1M ($4.35/share) in 2021.
- Cash $19.9M at 12/31/22 vs $35.7M at 12/31/21; operating cash used $25.2M; funds into Q4 2023.
- R&D $19.2M (up $1.6M); G&A $9.5M (up $3.0M) from prior year.
- Lawsuit resolved with WARF; non-exclusive license secured; all claims against Drs. Weichert and Pinchuk dismissed.
- Appointed Shane Lea as CCO and Dr. Andrei Shustov as SVP Medical; positive clinical data including CNS lymphoma complete response.

## SEC filing metadata
- accession: 0001104659-23-030354
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465923030354/0001104659-23-030354-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465923030354/tm238997d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-030354
- JSON: https://secwatch.observer/filing/0001104659-23-030354.json
- Plain text: https://secwatch.observer/filing/0001104659-23-030354.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.